Background: The incidence of active tuberculosis in HIV-infected patients receiving antiretroviral therapy (ART) is still significantly higher than that observed in the general population. We hypothesized that an optimal immunological recovery may reduce the risk of tuberculosis. Methodology: Historical cohort study in ART-treated patients without previous diagnosis of tuberculosis. Tuberculosis was diagnosed only if microbiologically proven. Multivariate analyses were performed to identify risk factors associated with tuberculosis. Results: This study included 1824 patients, with a median follow-up of 473 days. Higher CD4 count gain after ART initiation was a protective factor against active tuberculosis (per each 100 cells/μL increase, OR, 0.683; 95% CI, 0.522-0.894). The maximal protection was observed in patients reaching increments ≥150 cel/μL after 12 months (OR, 0.29; 95% CI 0.11-0.8) or ≥300 cel/μL after 24 months (OR, 0.73; 95% CI 0.71-0.75) of ART. CD4+ cell increase after ART initiation was confirmed as an independent predictor of development of tuberculosis by Cox regression analysis (per each 100 cell/uL at year one, HR 0.63; 95% CI, 0.43 – 0.94; per each 100 cell/uL at year two; HR, 0.57; 95% CI, 0.41 – 0.81). However, there was no association between achieving HIV RNA <50 copies/mL and the risk of active TB (OR, 1.43; 95% CI, 0.68-2.49). Conclusions: The risk of tuberculosis in patients starting ART is reduced among those with better immunological response and it is unrelated to the virological response. Our results emphasize the need of adjunctive strategies in immunological non-responders in order to minimize the residual risk of tuberculosis.